Recombinant Human Growth Hormone Ameliorates Cognitive Impairment in Stroke Patients

J Comput Assist Tomogr. 2020 Mar/Apr;44(2):255-261. doi: 10.1097/RCT.0000000000000990.

Abstract

Objective: We aimed to determine the effects of recombinant human growth hormone (rhGH) replacement on cognitive function in subjects with poststroke cognitive impairment using resting-state functional magnetic resonance imaging.

Methods: We included 60 patients with a first-ever stroke for 3 months and a diagnosis of cognitive impairment who were randomized 1:1 to receive either rhGH subcutaneously or placebo injection for 6 months. All subjects were required to receive the same rehabilitative therapy program. Both groups were subjected to pretreatment and posttreatment neuropsychological assessment using the Montreal Cognitive Assessment, serum neurotrophic factors, biomarkers of glucose and lipid metabolism, and functional magnetic resonance imaging during 6 months of the study period. The pattern of brain activity was determined by examining the functional connectivity and amplitude of low-frequency fluctuations (ALFF) of blood oxygen level dependent signal.

Results: Forty-three (82.7%) completed the study. Treatment with rhGH reduced levels of triglycerides and low-density lipoprotein cholesterol but did not significantly altered plasma concentrations of glucose and glycated hemoglobin. We found a significant increase in serum insulin-like growth factor 1 levels (32.6%; P < 0.001) in the rhGH-treated group compared with that in the controls. After 6 months of rhGH treatment, mean Montreal Cognitive Assessment score improved from 16.31 (5.32) to 21.19 (6.54) (P < 0.001). The rhGH group showed significant increased area of activation with increased ALFF values in the regions of the frontal lobe, putamen, temporal lobe, and thalamus (P < 0.05), relative to the baseline conditions. The correlation analysis revealed that the ALFF and functional connectivity of default mode network was positively correlated with the ΔMoCA score and ΔIGF-1 levels; that is, the more the scale score increased, the higher the functional connection strength. No undesirable adverse effects were observed.

Conclusions: The rhGH replacement has a significant impact on global and domain cognitive functions in poststroke cognitive impairment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Brain / diagnostic imaging
  • Brain / drug effects
  • Cognitive Dysfunction / complications*
  • Cognitive Dysfunction / drug therapy*
  • Female
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Stroke / complications*
  • Stroke / drug therapy*
  • Treatment Outcome

Substances

  • Human Growth Hormone